Antibacterial Drug Shortages From 2001 to 2013: Implications for Clinical Practice

Clinical Infectious Diseases

Volumn 60, Issue 12, 2015, Pages 1737-1742

  Quadri, Farha ^a   Mazer Amirshahi, Maryann ^b   Fox, Erin R ^c   Hawley, Kristy L ^d   Pines, Jesse M ^a,d   Zocchi, Mark S ^d   May, Larissa ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Drug shortages; National drug codes (NDC); University of Utah drug information service (UUDIS)

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CEFALEXIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFPODOXIME; CEFTIZOXIME; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COLISTIMETHATE; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN LACTOBIONATE; GENTAMICIN; IMIPENEM; KANAMYCIN; MEROPENEM; METHENAMINE; MINOCYCLINE; NAFCILLIN; PAROMOMYCIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN;

ARTICLE; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DRUG MANUFACTURE; DRUG SHORTAGE; HEALTH CARE AVAILABILITY; PRIORITY JOURNAL; RESOURCE MANAGEMENT; DRUG DATABASE; HUMAN; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; UNITED STATES;

ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; DATABASES, PHARMACEUTICAL; HUMANS; PUBLIC HEALTH; UNITED STATES;

EID: 84939517665     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ201     Document Type: Article

References (21)

1. Krisl JC, Fortier CR, Taber DJ. Disruptions in the supply of medications used in transplantation: implications and management strategies for the transplant clinician. Am J Transplant 2013; 13:20-30.
2. US Food and Drug Administration. Center for Drug Evaluation and Research. Office of New Drugs, Drug Shortage Management, 2012. Manual of policies and procedures. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/ucm079936.pdf. Accessed 28 August 2014.
3. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther 2013; 93:170-6.
4. Aitken M. Prescription drug shortages: examining a public health concern and potential solutions. Parsippany, NJ: IMS Institute for Healthcare Informatics, 2011.
5. Gundlapalli AV, Beekmann SE, Graham DR, Polgreen PM; Infectious Diseases Society of America's Emerging Infections Network. Perspectives and concerns regarding antimicrobial agent shortages among infectious disease specialists. Diagn Microbiol Infect Dis 2013; 75:256-9.
6. Gould IM. Coping with antibiotic resistance: the impending crisis. Int J Antimicrob Agents 2010; 36(suppl 3):S1-S2.
7. Spellberg B, Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014; 96:151-3.
8. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20:1170-5.
9. Drug Shortages: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability. US Government Accountability Office. Available at: http://www.gao.gov/products/GAO-14-194. Accessed 22 July 2014.
10. American Society of Health-System Pharmacists. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm 2009; 66:1399-406.
11. Fox ER, Tyler LS. Managing drug shortages: seven years' experience at one health system. Am J Health Syst Pharm 2003; 60:245-53.
12. Wagner AK, Soumerai FZ, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27:299-309.
13. Cochrane D, Orcutt GH. Application of least squares regression to relationships containing auto-correlated error terms. J Am Stat Assoc 1949; 44:32-61.
14. Griffith MM, Pentoney Z, Scheetz MH. Antimicrobial drug shortages: A crisis amidst the epidemic and the need for antimicrobial stewardship efforts to lessen the effects. Pharmacotherapy 2012; 32:665-7.
15. Wailan AM, Paterson DL. The spread and acquisition of NDM-1: A multifactorial problem. Expert Rev Anti Infect Ther 2014; 12: 91-115.
16. Biedenbach DJ, Bouchillon SK, Hoban DJ, et al. Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011). Diagn Microbiol Infect Dis 2014; 79:463-7.
17. Institute for Safe Medication Practices. Drug shortages: national survey reveals high level of frustration, low level of safety. Horsham, PA: Institute for Safe Medication Practices, 2010; 15.
18. Institute for Safe Medication Practices. A shortage of everything except errors: harm associated with drug shortages. Horsham, PA: Institute for Safe Medication Practices, 2012; 17.
19. Griffith MM, Patel JA, Sutton SH, et al. Prospective approach to managing antimicrobial drug shortages. Infect Control Hosp Epidemiol 2012; 33:745-52.
20. Valgas J, Singer EA, Berry SR, Kimryn Rathmell W. Ethical challenges: managing oncology drug shortages. J Oncol Pract 2013; 9:e21-3.
21. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria: time to react is now. Drug Resist Updat 2011; 14:118-24.